JP2012506904A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012506904A5 JP2012506904A5 JP2011534455A JP2011534455A JP2012506904A5 JP 2012506904 A5 JP2012506904 A5 JP 2012506904A5 JP 2011534455 A JP2011534455 A JP 2011534455A JP 2011534455 A JP2011534455 A JP 2011534455A JP 2012506904 A5 JP2012506904 A5 JP 2012506904A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- active ingredient
- pharmaceutically active
- mesoporous
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10901608P | 2008-10-28 | 2008-10-28 | |
| US61/109,016 | 2008-10-28 | ||
| PCT/SG2009/000053 WO2010050897A1 (en) | 2008-10-28 | 2009-02-18 | Mesoporous material excipients for poorly aqueous soluble ingredients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012506904A JP2012506904A (ja) | 2012-03-22 |
| JP2012506904A5 true JP2012506904A5 (enExample) | 2012-05-10 |
Family
ID=42129067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011534455A Pending JP2012506904A (ja) | 2008-10-28 | 2009-02-18 | 難水溶性成分のためのメソ多孔性材料賦形剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8778401B2 (enExample) |
| EP (1) | EP2349336B1 (enExample) |
| JP (1) | JP2012506904A (enExample) |
| KR (1) | KR20110110097A (enExample) |
| WO (1) | WO2010050897A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10026698A1 (de) | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
| US10952965B2 (en) * | 2009-05-15 | 2021-03-23 | Baxter International Inc. | Compositions and methods for drug delivery |
| CN103179955B (zh) | 2010-09-14 | 2016-08-03 | 纳诺洛吉卡股份公司 | 用于不良水溶性的药物和化妆活性成分的过饱和释放赋形剂 |
| KR101879474B1 (ko) | 2011-06-20 | 2018-07-17 | 하. 룬드벡 아크티에셀스카브 | 정신 분열증의 치료를 위한 중수소화 1-피페라지노-3-페닐 인단 |
| GB201212866D0 (en) * | 2012-07-20 | 2012-09-05 | Formac Pharmaceuticals Nv | Dry granulates of mesoporous silica powders |
| SI2916852T1 (sl) * | 2012-11-06 | 2021-08-31 | Sigrid Therapeutics Ab | Porozni silicijev dioksid za uporabo kot farmacevtska ali prehranska aktivna učinkovina |
| US9185928B2 (en) | 2012-12-21 | 2015-11-17 | National Health Research Institutes | Mesoporous silica nanoparticles for oil absorption |
| EP3125869A1 (en) * | 2014-03-31 | 2017-02-08 | Massachusetts Institute Of Technology | Porous materials containing compounds including pharmaceutically active species |
| CN104027814B (zh) * | 2014-05-29 | 2016-02-24 | 福州大学 | 一种通过氨基修饰后双重载药的介孔二氧化硅 |
| EP3517104A1 (en) * | 2014-08-01 | 2019-07-31 | Glenmark Pharmaceuticals S.A. | Nanoparticulate formulation comprising a mpges-1 inhibitor |
| EP3174527B1 (en) * | 2014-08-01 | 2021-02-17 | Johnson & Johnson Consumer Inc. | Dosage form of sodium ibuprofen dihydrate on mesoporous silica |
| GB201502073D0 (en) | 2015-02-09 | 2015-03-25 | Cubic Pharmaceuticals Ltd And Delta Pharmaceuticals Ltd | HDEG technology |
| US10252251B2 (en) | 2015-08-28 | 2019-04-09 | Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno | Production of organic materials using solid catalysts |
| US11903951B2 (en) * | 2016-06-03 | 2024-02-20 | M et P Pharma AG | Nasal pharmaceutical compositions with a porous excipient |
| CN106755231B (zh) * | 2016-11-29 | 2020-11-24 | 大连工业大学 | 一种血管紧张素转化酶抑制肽的提取方法 |
| CA3050361A1 (en) | 2017-01-20 | 2018-07-26 | M et P Pharma AG | Nasal pharmaceutical compositions for reducing the risks of exposure to air pollutants |
| EP3636282A4 (en) | 2017-05-19 | 2020-11-04 | Tokuyama Corporation | PHARMACEUTICAL EXCIPIENT AND ITS MANUFACTURING PROCESS |
| BR112021008732A2 (pt) | 2018-11-07 | 2021-08-03 | Disruptive Materials Pharma Ab | ingredientes farmacêuticos amorfos ativos compreendendo carbonato de magnésio mesoporoso substancialmente amorfo |
| US11123309B2 (en) | 2018-11-15 | 2021-09-21 | Imam Abdulrahman Bin Faisal University | Methods for drug delivery, tumor imaging, and oxidative dehydrogenation using hierarchical ZSM-5 complex |
| EP3891134A1 (en) | 2018-12-03 | 2021-10-13 | H. Lundbeck A/S | Prodrugs of 4-((1r,3s)-6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1/r,3s)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1h-inden-1-yl)-2,2-dimethy-1-(methyl-d3)piperazine |
| US20200188301A1 (en) | 2018-12-14 | 2020-06-18 | NuVessl, Inc. | Method for Enhancing Passenger Molecule Loading |
| US20220096398A1 (en) * | 2019-01-31 | 2022-03-31 | Macquarie University | Complexes and compositions comprising probucol and uses thereof |
| JP7260353B2 (ja) * | 2019-03-25 | 2023-04-18 | 株式会社ファンケル | コエンザイムｑ１０の固体分散体 |
| GB201909137D0 (en) * | 2019-06-25 | 2019-08-07 | Univ Aston | Mesoporous polymeric particulate material |
| JP2021042173A (ja) * | 2019-09-12 | 2021-03-18 | 株式会社ファンケル | クルクミン固体分散体 |
| US20240016739A1 (en) * | 2020-05-06 | 2024-01-18 | Disruptive Pharma Ab | Novel amorphous active pharmaceutical ingredients |
| CN115300448A (zh) * | 2021-05-06 | 2022-11-08 | 香港中文大学 | 在纳米多孔模板内实现材料的纳米非晶态 |
| US12458602B2 (en) | 2021-05-06 | 2025-11-04 | The Chinese University Of Hong Kong | Realizing the nano-amorphous state of materials inside nano-porous templates |
| WO2022235934A2 (en) * | 2021-05-06 | 2022-11-10 | The Chinese University Of Hong Kong | Realizing the nano-amorphous state of materials inside nano-porous templates |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1227626B (it) * | 1988-11-28 | 1991-04-23 | Vectorpharma Int | Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione |
| DE4327063A1 (de) | 1993-08-12 | 1995-02-16 | Kirsten Dr Westesen | Ubidecarenon-Partikel mit modifizierten physikochemischen Eigenschaften |
| US5922299A (en) * | 1996-11-26 | 1999-07-13 | Battelle Memorial Institute | Mesoporous-silica films, fibers, and powders by evaporation |
| US7919119B2 (en) | 1999-05-27 | 2011-04-05 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| US7172770B2 (en) | 2001-02-19 | 2007-02-06 | Board Of Regents, The University Of Texas System | Mesoporous compositions for use in drug delivery |
| US6630170B2 (en) * | 2001-04-26 | 2003-10-07 | Board Of Regents The University Of Texas System | Mesoporous compositions and method of preparation |
| CZ20033456A3 (en) * | 2001-06-22 | 2004-07-14 | Pfizer Products Inc. | Pharmaceutical compositions comprising adsorbates of amorphous drug |
| US6653319B1 (en) | 2001-08-10 | 2003-11-25 | University Of Kentucky Research Foundation | Pharmaceutical formulation for poorly water soluble camptothecin analogues |
| GB0315012D0 (en) * | 2003-06-27 | 2003-07-30 | Leuven K U Res & Dev | Zeotiles |
| WO2005082277A1 (en) | 2004-02-18 | 2005-09-09 | Stanford University | Drug delivery systems using mesoporous oxide films |
| WO2005110592A1 (en) * | 2004-05-17 | 2005-11-24 | Yki, Ytkemiska Institutet Ab | Mesoporous particles loaded with active substance |
-
2009
- 2009-02-18 US US13/126,160 patent/US8778401B2/en active Active
- 2009-02-18 WO PCT/SG2009/000053 patent/WO2010050897A1/en not_active Ceased
- 2009-02-18 JP JP2011534455A patent/JP2012506904A/ja active Pending
- 2009-02-18 EP EP09823913.0A patent/EP2349336B1/en active Active
- 2009-02-18 KR KR1020117012169A patent/KR20110110097A/ko not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012506904A5 (enExample) | ||
| Patel et al. | Xanthan gum derivatives: Review of synthesis, properties and diverse applications | |
| Javanbakht et al. | Carboxymethyl cellulose-based oral delivery systems | |
| CN112004520B (zh) | 包括具有触发脉冲药物释放的胃内滞留筏形成系统的调节释放药物粉末组合物 | |
| JP2008503475A5 (enExample) | ||
| US20210244671A1 (en) | Monolithic tablets based on carboxyl polymeric complexes for controlled drug release | |
| Shilpa et al. | Controlled delivery of drugs from alginate matrix | |
| CN101466359B (zh) | 快速释放的对乙酰氨基酚片 | |
| CA3097737A1 (en) | Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system | |
| WO2019126214A1 (en) | Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release | |
| Bera et al. | Facile synthesis and characterization of tailor-made pectin-gellan gum-bionanofiller composites as intragastric drug delivery shuttles | |
| Nayak et al. | Gellan gum-based nanomaterials in drug delivery applications | |
| WO2011135591A2 (en) | Novel tablet composition of polyallylamine polymers | |
| Xie et al. | Efficient antibacterial agent delivery by mesoporous silica aerogel | |
| JP2011241218A5 (enExample) | ||
| Mali et al. | Delivery of drugs using tamarind gum and modified tamarind gum: A review | |
| WO2011160541A1 (zh) | 托伐普坦固体分散体及其制备方法 | |
| Olayemi et al. | Formulation and evaluation of Cyperus esculentus (Tiger Nut) starch-alginate microbeads in the oral delivery of ibuprofen | |
| WO2019184994A1 (zh) | 一种提高缬沙坦溶解性的环糊精-金属有机骨架组合物 | |
| WO2008086844A2 (en) | Co-precipitate, method for preparing the same and uses thereof | |
| JP2011513393A5 (enExample) | ||
| RU2004117848A (ru) | Система продолжительного высвобождения растворимого лекарственного средства | |
| JP2010521437A5 (enExample) | ||
| JP2002536318A5 (enExample) | ||
| Hasnain et al. | Graft copolymers of chitosan in drug delivery applications |